Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Nitazoxanide  COVID-19 treatment studies for Nitazoxanide  C19 studies: Nitazoxanide  Nitazoxanide   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality -206% Improvement Relative Risk Hospitalization 79% Severe case 85% Severe case (b) 84% Time to sustained recovery -7% primary Rossignol et al. NCT04486313 Nitazoxanide RCT EARLY Is early treatment with nitazoxanide beneficial for COVID-19? Double-blind RCT 379 patients in the USA (August 2020 - February 2021) Higher mortality (p=0.49) and lower hospitalization (p=0.22), not stat. sig. Rossignol et al., eClinicalMedicine, doi:10.1016/j.eclinm.2022.101310 Favors nitazoxanide Favors control
A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19
Rossignol et al., eClinicalMedicine, doi:10.1016/j.eclinm.2022.101310 (date from earlier preprint), NCT04486313 (history)
Rossignol et al., A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate.., eClinicalMedicine, doi:10.1016/j.eclinm.2022.101310 (date from earlier preprint), NCT04486313
Mar 2022   Source   PDF  
  All Studies   Meta
RCT with 184 outpatients treated with an extended release formulation of nitazoxanide, and 195 controls, showing lower hospitalization and progression to severe disease with treatment. There was one COVID-19 related death in the treatment arm. 600mg twice daily for five days. NCT04486313 (history).
risk of death, 206.0% higher, RR 3.06, p = 0.49, treatment 1 of 184 (0.5%), control 0 of 195 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), COVID-19 deaths.
risk of hospitalization, 78.8% lower, RR 0.21, p = 0.22, treatment 1 of 184 (0.5%), control 5 of 195 (2.6%), NNT 49.
risk of severe case, 84.9% lower, RR 0.15, p = 0.07, treatment 1 of 184 (0.5%), control 7 of 195 (3.6%), NNT 33.
risk of severe case, 83.9% lower, RR 0.16, p = 0.07, treatment 1 of 112 (0.9%), control 7 of 126 (5.6%), NNT 21, high-risk subgroup.
time to sustained recovery, 7.3% higher, relative time 1.07, p = 0.88, treatment 184, control 195, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rossignol et al., 31 Mar 2022, Double Blind Randomized Controlled Trial, USA, peer-reviewed, 5 authors, study period August 2020 - February 2021, average treatment delay 1.83 days, trial NCT04486313 (history).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperNitazoxanideAll
Abstract: Articles A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19 Jean-François Rossignol,a Matthew C. Bardin,a Jessica Fulgencio,a Dena Mogelnicki,a and Christian Brechot a,b,c*, for the Vanguard Study Group 1 a Romark Institute of Medical Research, Tampa, FL, United States University of South Florida, College of Medicine, Tampa, FL, United States c Global Virus Network, United States b Summary Background There is an urgent need for treatments of mild or moderate COVID-19 in an outpatient setting. Methods A randomized double-blind placebo-controlled clinical trial in 36 centers in the U.S. between August 2020 and February 2021 investigated the safety and effectiveness of oral nitazoxanide 600 mg twice daily for five days in outpatients with symptoms of mild or moderate COVID-19 enrolled within 72 h of symptom onset (ClinicalTrials. gov NCT04486313). Efficacy endpoints were time to sustained clinical recovery (TSR, a novel primary endpoint) and proportion of participants progressing to severe illness within 28 days (key secondary). eClinicalMedicine 2022;45: 101310 Published online xxx eclinm.2022.101310 Findings 1092 participants were enrolled. 379 with laboratory-confirmed SARS-CoV-2 infection were analyzed. In the primary analysis, median (IQR) TSR were 13¢3 (6¢3, >21) and 12¢4 (7¢2, >21) days for the nitazoxanide and placebo groups, respectively (p = 0¢88). 1 of 184 (0¢5%) treated with nitazoxanide progressed to severe illness compared to 7 of 195 (3¢6%) treated with placebo (key secondary analysis, odds ratio 5¢6 [95% CI 0¢7 - 46¢1], relative risk reduction 85%, p = 0¢07). In the pre-defined stratum with mild illness at baseline, nitazoxanide-treated participants experienced reductions in median TSR (3¢1 days, p = 0¢09) and usual health (5¢2 days, p < 0¢01) compared to placebo. Nitazoxanide was safe and well tolerated. Interpretation Further trials with larger numbers are warranted to evaluate efficacy of nitazoxanide therapy in preventing progression to severe illness in patients at high risk of severe illness and reducing TSR in patients with mild illness. Copyright Published by Elsevier Ltd. This is an open access article under the CC BY license (http://
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop